A more effective and better-tolerated treatment for chronic myeloid leukemia (CML) could improve quality of life for people ...

A new review maps how FLT3 inhibitors became standard therapy across newly diagnosed and relapsed AML while trials test ...

Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -- Company to Report Topline Primary Endpoint ...

Key TakeawaysSellas shares fell 18% today after the company said its Phase 3 REGAL trial in acute myeloid leukemia reached the 80th death, which triggers the trial’s final analysis. The drop looks ...

Sellas’ Phase 3 Regal leukemia trial reached its 80th event, triggering final analysis. ・Preliminary topline results are due ...

High CD84 expression correlates with venetoclax resistance in AML, and targeting the CD84-SESN2 pathway sensitized leukemia ...

The exact cause of acute myeloid leukemia (AML) is unclear, but risk factors can include older age, radiation exposure, smoking, certain genetic conditions, and more. Acute myeloid leukemia (AML) is a ...

The activity of six different genes can help determine survival in patients with acute myeloid leukemia (AML), according to a ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

Acute myeloid leukemia (AML) is not hereditary, but a person may inherit gene mutations that make the condition more likely. Having a close family member with AML can also increase the risk. Acute ...